Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31056124 | 0.89 | MAPT (0.50) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL24983810 | 0.88 | MAPT (0.51) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL2908502 | 0.87 | FFAR4 (0.49) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL1539204 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL20139428 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL20139379 | 0.84 | PTPN1 (0.61) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL207723 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL20563703 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL2171253 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD | |
| SCHEMBL187045 | 0.83 | MAPT (0.60) | SMN1; SMN2MAPTL3MBTL1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-03-09 | — | — | US | disclosed |
| EP-3860984-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-20210238170-A1 | 5,5-Difluoro- and 5-Fluoro-5-Methyl-C-Glycoside Derivatives Useful As Dual SGLT1 / SGLT2 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-05 | — | — | US | disclosed |
| CN-112912371-A | Flavone derivatives for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| CN-107311992-B | C-aryl glucoside derivative, preparation method and application thereof in medicine | 上海研健新药研发有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-20100004465-A1 | C-PHENYL 1-THIOGLUCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611023-A | The 1-phenyl 1-thio-D-glucitol derivative | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103607-A1 | 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-09-23 | — | — | EP | disclosed |
| CN-101490028-A | C-phenyl glycitol compound for the treatment of diabetes | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2076503-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-2036901-A1 | C-PHENYL 1-THIOGLUCITOL COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| CN-101103013-A | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| WO-2007136116-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-29 | — | — | WO | disclosed |
| EP-1845095-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | SMN1; SMN2 3695/4885MAPT 1495/4885L3MBTL1 4251/4885 |
| US-20100004465-A1 | C-PHENYL 1-THIOGLUCITOL COMPOUND | SLC5A1, SLC5A2, SLC2A1 | SMN1; SMN2 4505/4885MAPT 1989/4885L3MBTL1 3293/4885 |
| US-20210238170-A1 | 5,5-Difluoro- and 5-Fluoro-5-Methyl-C-Glycoside Derivatives Useful As Dual SGLT1 / SGLT2 Modulators | SLC5A2, SLC5A1, SLC2A4 | SMN1; SMN2 3525/4885MAPT 550/4885L3MBTL1 4304/4885 |
| US-11708344-B2 | Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease | CCNE2, CCNE1, CCNT1 | SMN1; SMN2 3705/4885MAPT 3335/4885L3MBTL1 1655/4885 |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | SLC5A1, SLC5A2, SLC5A11 | SMN1; SMN2 4001/4885MAPT 621/4885L3MBTL1 1990/4885 |
| US-20230074887-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | CCNE2, CCNE1, CCNT1 | SMN1; SMN2 3705/4885MAPT 3335/4885L3MBTL1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.